PubMed Health⌕ Search

Biomedical subjects

C Moroz

Publications and source records attributed to C Moroz.

At least 37 records · Page 2Linked to original sources
PubMed1987

Placental type isoferritins in chronic liver diseases.

Serum ferritin levels in chronic liver diseases were measured by an enzyme-linked immunosorbent assay (ELISA) using two monoclonal antibodies (McAb) against placental ferritin. One of the McAbs (CM-H9) recognizes a specific placental-like isoferritin (PLF) only, while the other McAb (CM-G8) recognizes an isoform (CF) common to human placenta, liver and spleen. The different diseases studied were primary biliary cirrhosis (PBC-14 patients), chronic active hepatitis (CAH-12 patients), alcoholic cirrhosis (AC-18 patients) and cryptogenic cirrhosis (CRY-26 patients). Increased levels of both isoferritine were found in all these liver disorders, with an overall incidence of 80% for CF and 40% for PLF. The mean level of CF was significantly above normal in PBC, AC and CRY and that of PLF in PBC and CRY. Circulating placental-type isoferritins have not been previously described in patients with liver disorders. Our findings indicate that elevation of serum ferritin in liver diseases is caused by different isoferritin components.

Antibodies, Monoclonal↗
PubMed1987

Difference in the placental ferritin levels measured by a specific monoclonal antibody enzymoassay in preterm and term delivery.

The use of a new monoclonal antibody (MoAb) enzymoassay for the specific measurement of placental ferritin (PLF) enabled it to be quantitatively determined in the sera of pregnant women, women at full-term and preterm delivery, and in their newborns. High levels of PLF were measured in the sera of pregnant women at 17 weeks of gestation up to full-term delivery as compared with normal adult women who mostly lack PLF. The level of PLF in the serum was irrespective of the total ferritin level. In full-term newborns, PLF concentration was lower than that found in their mothers although it increased compared to healthy adults. It was further found that in the blood of women who delivered at 29-36 weeks, PLF was undetected or was very low. Accordingly their preterm infants also exhibited very low or undetectable PLF in their serum. These results suggest the possible use of PLF as a prognostic indicator in pregnancy.

Adult↗
PubMed1987

New monoclonal antibody enzymoassay for the specific measurement of placental ferritin isotype in hematologic malignancies.

A new enzymoimmunoassay, specific for the measurement of placental ferritin (PLF) isotype, has been described. Two monoclonal antibodies (McAbs) with different binding specificities to placental ferritin have been used in this assay. One antibody (CM-G-8) binds to all ferritins, whereas the second (CM-H-9) binds to placental ferritin only. In addition, a second enzymoassay was developed for the measurement of total common serum ferritin using CM-G-8 McAb. Serum levels of total ferritin and PLF were measured in healthy individuals and in patients with lymphoproliferative diseases and multiple myeloma. The majority of normal subjects were deficient in PLF in the serum. Increased serum levels of PLF were observed in patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma of low and intermediate grades, as well as in patients with acute lymphocytic leukemia (ALL). Total ferritin was also elevated in these patients. Chronic lymphocytic leukemia (CLL) and multiple myeloma patients exhibited normal levels of common serum ferritin, whereas PLF in the serum was lacking.

Antibodies, Monoclonal↗
PubMed1985

Preparation and characterization of monoclonal antibodies specific to placenta ferritin.

Ferritins are a group of isomeric proteins which function as the major iron-storage protein of mammalian tissues. Some of the isoferritins have low isoelectric points, and are found in placenta and in malignant tissues and have therefore been termed carcinofetal ferritins. With the use of hybridoma technology, monoclonal antibodies (McAbs) specific to human placenta ferritin(s) were produced in order to characterize the heterogeneity of the molecule and to answer the question whether a specific antigenic determinant is associated with placenta and/or carcinofetal ferritin(s). Two McAbs designated H-9 and G-8 were developed. McAb H-9 bound specifically and exclusively to the ferritin isolated from human placenta, whereas G-8 McAb bound to placenta ferritin and cross-reacted with ferritins isolated from human spleen and liver. No cross-reaction was observed between H-9 and G-8 reactive determinants. It was found further that the two antigenic determinants - the one recognized by G-8 and that recognized by H-9 McAbs - are molecularly associated on placenta ferritin. The results of this study led us to term the G-8 a 'common' ferritin antigenic determinant and H-9 a 'private' embryonic ferritin determinant.

Animals↗
PubMed1985

Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.

Considerable interest has been focused on the use of interferon (IFN) and IFN-inducers as antineoplastic agents in humans. The current report will focus on the effect of intravesical administration of Poly I: Poly C on NK activity in patients with TCC of the urinary bladder. NK cytotoxicity was measured in 14 patients with primary TCC, 8 patients received Poly I: Poly C and 5 other patients received intravesical thiotepa. Blood samples were obtained prior to and 48 h following each drug treatment. A variation in the initial NK level determined prior to treatment was observed in the different TCC patients: 5 patients treated with Poly I: Poly C and 5 patients treated with thiotepa exhibited low NK activity prior to treatment, whereas the other 3 patients who were treated with Poly I: Poly C had high initial NK levels. Following drug treatment it was shown that a significant elevation in the NK cytotoxicity was only observed in patients treated by intravesical Poly I: Poly C who had low NK activity prior to treatment. No such effect was observed in patients treated with thiotepa or in patients treated with Poly I: Poly C who exhibited a high NK activity prior to treatment.

Adult↗
PubMed1985

The regulatory role of adenosine activated T-lymphocyte subset on the immune response in humans. II. Adenosine induced expression of T8 antigen.

Adenosine sensitive suppressor T cells (ESen) were isolated from healthy donors and continuous cultures of these cells were established. It was found that the continuous proliferation of ESen cells required IL-2, Adenosine and ConA. The reactivity of ESen cells with OKT3, OKT4 and OKT8 monoclonal antibodies was studied before and after incubation with adenosine. The majority of freshly isolated ESen cells were OKT8+ cells. During culture, the majority of the proliferating ESen cells were OKT4; however, following a brief incubation of cultured ESen cells with adenosine, an increase in OKT8+ cells and a decrease in OKT4+ cells were observed. A fraction of ESen cells exhibited simultaneously OKT4+ and OKT8+ antigens similar to thymocytes. Furthermore, adenosine treatment of thymocytes resulted in a small increase in OKT8+ and OKT3+ cells and a parallel decrease in OKT4+ cells. These results indicate that adenosine may play a regulatory role in the differentiation of lymphocytes programmed to carry out a specific function.

Adenosine↗
PubMed1984

Ferritin-bearing lymphocytes in the diagnosis of breast cancer.

Four hundred forty-seven women attending a breast clinic because of either suspicious lesions, anxiety about breast cancer, follow-up after the removal of a benign breast lesion, or a family history of breast cancer had a routine test for percentage of ferritin-bearing lymphocytes ( FBL ) in their peripheral blood. Among patients who received surgery following physical examination in the clinic and/or mammography, the test was positive in 40 of the 45 (89%) with Stage I;II carcinoma, 3 of 3 with Stage IV carcinoma, and only in 29 of the 97 (37%) with benign breast disease. The possible reasons for the poorer detection rate in Stage III carcinoma are discussed. The test, however, identified 2 cases of Stage I carcinoma, 1 of breast lymphoma, and 12 with premalignant lesions in those who were found normal on physical examination and mammography. Ferritin-bearing lymphocyte results tended to become negative after surgical removal of the lesion, and became positive on recurrence of the tumor and appearance of metastases. The detection rate was maximized by combining the FBL test with the clinical modes of detection.

Adult↗
PubMed1979

Immunodiagnostic test for the early detection of carcinoma of the breast.

A cytotoxic assay for the identification of circulating lymphocytes bearing surface ferritin was performed on 100 patients with malignant disease of the breast and in 50 healthy women. Forty-five patients were found to have a subpopulation of ferritin bearing lymphocytes, and all of them proved to have Stages I and II carcinoma of the breast. No such lymphocytes were identified in normal women, and in the remaining 55 patients, 33 had benign disease of the breast, 20 had Stage III carcinoma of the breast and two had Stages I and II carc-noma of the breast. It appears that this immunodiagnostic test may provide an additional tool for the early detection of carcinoma of the breast and may have a prognostic implication.

Breast Neoplasms↗
PubMed1977

The mutual clonal origin of the lymphoplasmocytic and lymphoma cell in alpha-heavy chain disease.

Biosynthetic studies in alpha-heavy chain disease were performed on the gut tumour which was composed mainly of lymphoplasmocytic cells and on the mesenteric lymph node tumour composed mainly of immunoblasts. The gut tumour cells synthesised alpha-heavy chains and secreted them during 2-5 hr culture, whereas the lymph node tumour cells synthesized alpha-heavy chains which were shed into the culture medium only after 20 hr. These chains were shown to be present on the surface of the immunoblastic tumour cells by enzymatic radioiodination. Both the surface and the secreted alpha-heavy chain of the lymph node and gut tumour were found to be smaller than the alpha-heavy chain of myeloma proteins. These results suggest that the lymphoblasmocytic and the immunoblastic tumour cells originate from the same defective clone.

Adult↗
PubMed1977

Ferritin on the surface of lymphocytes in Hodgkin's disease patients. A possible blocking substance removed by levamisole.

Enzymatic radioiodination of surface proteins of Hodgkin's disease peripheral blood mononuclear cells revealed the presence of a blocking protein on their surface. This protein shed into the medium after incubation with levamisole, which resulted in the unmasking of surface proteins similar to those on normal monunuclear cells. The blocking substance was identified. It reacted with anti-human spleen ferritin. It had no detectable iron and dissociated into monomeric subunits of 18,000 mol. wt. by reduction and alkylation, and therefore it is most probably apoferritin rather than ferritin.

Apoferritins↗